Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "CHEMI"

813 News Found

Jubilant Ingrevia appoints Vijay Srivastava as Chief of Operations
People | October 23, 2024

Jubilant Ingrevia appoints Vijay Srivastava as Chief of Operations

He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates


Health Minister Nadda inaugurates Medicine Update BJMFCON 2024
Policy | October 21, 2024

Health Minister Nadda inaugurates Medicine Update BJMFCON 2024

Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020


JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
Sustainability | October 21, 2024

JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24

JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%


Gland Pharma appoints Shyamakant Giri as CEO
People | October 19, 2024

Gland Pharma appoints Shyamakant Giri as CEO

Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals


Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network
News | October 09, 2024

Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network

WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse


Lupin acquires nine brands of Medical Nutritional Institute in South Africa
News | October 06, 2024

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome


Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
News | October 05, 2024

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025


Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
Drug Approval | October 04, 2024

Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin

This is used to treat central diabetes insipidus and bedwetting


Avient expands healthcare TPU manufacturing in China
News | September 27, 2024

Avient expands healthcare TPU manufacturing in China

Showcases specialty and sustainable materials for healthcare at Medtec China 2024